» Articles » PMID: 20307660

Loss of Collagen-receptor DDR1 Delays Renal Fibrosis in Hereditary Type IV Collagen Disease

Overview
Journal Matrix Biol
Publisher Elsevier
Date 2010 Mar 24
PMID 20307660
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Alport syndrome is a hereditary type IV collagen disease leading to progressive renal fibrosis, hearing loss and ocular changes. End stage renal failure usually develops during adolescence. COL4A3-/- mice serve as an animal model for progressive renal scarring in Alport syndrome. The present study evaluates the role of Discoidin Domain Receptor 1 (DDR1) in cell-matrix interaction involved in pathogenesis of Alport syndrome including renal inflammation and fibrosis. DDR1/COL4A3 Double-knockouts were compared to COL4A3-/- mice with 50% or 100% expression of DDR1, wildtype controls and to DDR1-/- COL4A3+/+ controls for over 6years. Double-knockouts lived 47% longer, mice with 50% DDR1 lived 29% longer and showed improved renal function (reduction in proteinuria and blood urea nitrogen) compared to animals with 100% DDR1 expression. Loss of DDR1 reduced proinflammatory, profibrotic cells via signaling of TGFbeta, CTGF, NFkappaB and IL-6 and decreased deposition of extracellular matrix. Immunogold-staining and in-situ hybridisation identified podocytes as major players in DDR1-mediated fibrosis and inflammation within the kidney. In summary, glomerular epithelial cells (podocytes) express DDR1. Loss of DDR1-expression in the kidney delayed renal fibrosis and inflammation in hereditary type IV collagen disease. This supports our hypothesis that podocyte-matrix interaction via collagen receptors plays an important part in progression of renal fibrosis in Alport disease. The blockade of collagen-receptor DDR1 might serve as an important new therapeutic concept in progressive fibrotic and inflammatory diseases in the future.

Citing Articles

Discoid Domain Receptors Signaling in Macrophages-Mediated Diseases.

Ma Y, Gong H, Cheng L, Zhang D Int J Gen Med. 2025; 18:907-926.

PMID: 39990299 PMC: 11847422. DOI: 10.2147/IJGM.S487093.


Exploration of Gene Therapy for Alport Syndrome.

Zhao Y, Zheng Q, Xie J Biomedicines. 2024; 12(6).

PMID: 38927366 PMC: 11200676. DOI: 10.3390/biomedicines12061159.


Progress in therapeutic targets on podocyte for Alport syndrome.

Zheng Q, Gu X, He J, Xie J J Transl Int Med. 2024; 12(2):129-133.

PMID: 38812923 PMC: 11135632. DOI: 10.2478/jtim-2024-0005.


Exploring the Cellular and Molecular Mechanism of Discoidin Domain Receptors (DDR1 and DDR2) in Bone Formation, Regeneration, and Its Associated Disease Conditions.

Mariadoss A, Wang C Int J Mol Sci. 2023; 24(19).

PMID: 37834343 PMC: 10573612. DOI: 10.3390/ijms241914895.


iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome.

Hirayama R, Toyohara K, Watanabe K, Otsuki T, Araoka T, Mae S Commun Biol. 2023; 6(1):854.

PMID: 37770589 PMC: 10539496. DOI: 10.1038/s42003-023-05203-4.